The Brief Brief Longevity
the slow science of staying alive longer.
Longevity — briefly, then briefly again · tbb.ceo
listen tothe daily 0:00 –:––
/daily ·16 NOV 2026 ·MONDAY ·2 MIN READ ·4 STORIES

What the trials actually show

Four studies published this week benchmark longevity interventions and map new biology of cellular aging: a 51-trial meta-analysis reveals which treatments show epigenetic age reduction and which do not, researchers chart 2,132 RNA editing sites that shift with senescence, a mouse study identifies a new regulator of cellular aging onset, and an observational study links estrogen exposure history to brain vessel health.

01 / The Day

MONDAY 16 NOV 2026, ranked

04

51 Anti-Aging Trials Benchmarked: What Actually Slows Biological Aging

A systematic benchmark of 51 clinical trials found that statins, metformin, GLP-1 agonists, and regular exercise each produced measurable reductions in biological age across multiple epigenetic clocks. Popular supplements including NMN, NR, and resveratrol showed no statistically significant effect in any of the 16 clocks tested.

  • Statins, metformin, GLP-1 agonists, and exercise showed consistent reductions across 16 epigenetic clock measures
  • NMN, NR, and resveratrol found ineffective at reducing biological aging in controlled trial data
  • TranslAGE framework enables standardized comparison across heterogeneous trial designs
Why it mattersThis is the most rigorous cross-trial comparison of longevity interventions to date, providing a framework for evaluating future trials against a common benchmark.

Scientists Map 2,132 RNA Editing Sites That Change With Aging

Researchers identified 2,132 senescence-associated RNA editing sites, 92% of which lie in Alu repeat elements within 3' untranslated regions. Editing at the F11R gene locus correlates strongly with aging across multiple human tissue datasets.

  • 2,132 RNA editing sites identified that change as cells enter senescence
  • 92% located in Alu elements in 3' UTRs — suggesting ADAR enzyme regulation
  • F11R editing change validated as an aging biomarker across independent datasets
Why it mattersSenescence-linked RNA editing is an underexplored layer of gene regulation — these sites could become targets for drugs that delay cellular aging.

Blocking a Protein Interaction Delays Cellular Senescence in Mice

A study in mice found that disrupting the interaction between deubiquitinase USP25 and longevity regulator SIRT1 slowed the onset of cellular senescence in multiple tissues, suggesting USP25 normally suppresses SIRT1's protective activity.

  • USP25 inhibition allowed SIRT1 to remain active longer, delaying senescence markers
  • Tissue analysis showed reduced p21, p16, and SA-β-gal staining in treated mice
  • Effect observed in liver, kidney, and lung tissue at 18 and 24 months of age
Why it mattersSIRT1 is a well-established longevity regulator, but its upstream controllers are poorly mapped — USP25 emerges as a tractable new target.

Longer Estrogen Exposure Linked to Less Brain Vessel Disease in 352 Women

An observational study of 352 postmenopausal women found that those with longer cumulative estrogen exposure — from earlier menarche, later menopause, or longer use of hormonal contraceptives — showed significantly lower rates of cerebral small vessel disease on MRI.

  • Each additional year of estrogen exposure associated with 6% lower small vessel disease burden
  • Effect independent of hypertension, smoking, and diabetes after adjustment
  • Observational design: correlation only, not evidence of causation
Why it mattersCerebral small vessel disease is a leading cause of vascular dementia; this study adds to evidence linking reproductive hormone history to brain aging trajectories.
Be subscriber #028 topic interest list · email delivery not yet available
Past days

The Daily Archive